Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Allergan plc (NYSE:AGN)

246.32
Delayed Data
As of Feb 22
 -0.84 / -0.34%
Today’s Change
184.50
Today|||52-Week Range
301.32
+17.29%
Year-to-Date
AGN Regular Dividend: AGN will begin trading ex-dividend on 02/24/17 with a $0.70 dividend payable to shareholders of record as of 02/28/17.
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Feb 22 / TheStreet.com - Paid Partner Content
Medtronic Earnings Rebound in Third Quarter, Shares Climb
Feb 21 / TheStreet.com - Paid Partner Content
North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Communi...
Feb 22 / GuruFocus News - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Alle...
Feb 21 / Zacks.com - Paid Partner Content
Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top
Feb 22 / Zacks.com - Paid Partner Content
Big pharma bets billions on 'silent' liver disease
Feb 21 / FT.com - Paid Partner Content
Go With Allergan, Celgene and 'Big Mo'
Feb 22 / TheStreet.com - Paid Partner Content
Riddle Me This; Bendable Market: Best of Kass
Feb 17 / TheStreet.com - Paid Partner Content
Where Are the Best Buying Opportunities in Stocks Right Now?
Feb 21 / Zacks.com - Paid Partner Content
Deals of the Week: Valentine Couplings and Breakups
Feb 17 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close247.16
Today’s open247.26
Day’s range246.02 - 249.00
Volume1,920,148
Average volume (3 months)4,752,753
Market cap$92.4B
Dividend yield1.14%
Data as of 02/22/2017

Growth & Valuation

Earnings growth (last year)+281.42%
Earnings growth (this year)+18.85%
Earnings growth (next 5 years)+11.50%
Revenue growth (last year)-3.32%
P/E ratioNM
Price/Sales5.55
Price/Book--

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb+0.57+1.04%
CELGCelgene-0.17-0.14%
LLYEli Lilly and Co+0.71+0.88%
ABBVAbbVie-0.47-0.76%
Data as of 4:02pm ET, 02/22/2017

Financials

Next reporting dateMay 3, 2017
EPS forecast (this quarter)$3.40
Annual revenue (last year)$14.6B
Annual profit (last year)$15.0B
Net profit margin-6.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chairman, President &
Chief Executive Officer
Brenton L. Saunders
Chief Operating Officer
Robert A. Stewart
Corporate headquarters
Dublin, Dublin

Forecasts


Search for Jobs